Sansó Sureda Andrés, Rocamora Durán Vicenç, Sapiña Camaró Amparo, Royo Escosa Vanesa, Bosque López María José
Servicio de Digestivo, Hospital de Manacor, Manacor, Baleares, España.
Gastroenterol Hepatol. 2011 Oct;34(8):546-50. doi: 10.1016/j.gastrohep.2011.04.003. Epub 2011 Jun 12.
Treatment with anti-tumor necrosis factor (TNF)-α for Crohn's disease is relatively safe, although various cutaneous adverse effects have been reported such as the development or exacerbation of anti-TNF- α-induced psoriasis, which can sometimes lead to treatment withdrawal. Therefore, new alternative treatments with new mechanisms of action are required. Ustekinumab, a monoclonal antibody against the p40 subunit of interleukin 12/23, could induce response in patients with Crohn's disease and has demonstrated efficacy in patients with psoriasis. We present the case of a woman with Crohn's disease who developed psoriasis after treatment with two anti-TNF- α drugs (infliximab and adalimumab). The patient was subsequently treated with ustekinumab with resolution or psoriasis lesions and maintenance of remission of Crohn's disease.
尽管已报道了各种皮肤不良反应，如抗TNF-α诱导的银屑病的发生或加重，有时这会导致停止治疗，但用抗肿瘤坏死因子（TNF）-α治疗克罗恩病相对安全。因此，需要具有新作用机制的新的替代治疗方法。乌司奴单抗是一种针对白细胞介素12/23的p40亚基的单克隆抗体，可在克罗恩病患者中诱导反应，并已在银屑病患者中显示出疗效。我们报告了一名患有克罗恩病的女性病例，该患者在用两种抗TNF-α药物（英夫利昔单抗和阿达木单抗）治疗后出现了银屑病。该患者随后接受了乌司奴单抗治疗，银屑病皮损消退，克罗恩病维持缓解。
